Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

½Å»ý¾Æ °£³» ´ãÁó Á¤Ã¼ÁõÀÇ ¿¹ÈÄ ÀÎÀÚ:ºñ°¡Á·¼º, ºñ´ë»ç¼º, ºñÁõÈļº ´ãÁó Á¤Ã¼Áõ Predictive Factors for Prognosis of Neonatal Intrahepatic Cholestasis: Non-Familial, Non-Metabolic, Non-Syndromic Cholestasis

´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸÁö 2004³â 7±Ç 2È£ p.208 ~ 214
±èÇü¼®, ±èÀÎÁÖ, ¹ÚÀçÈ«, ÀÌâÈÆ,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÇü¼® ( Kim Hyung-Suck ) 
ºÎ»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç

±èÀÎÁÖ ( Kim In-Joo ) 
ºÎ»ê´ëÇб³ ÀÇ°ú´ëÇÐ ÇÙÀÇÇб³½Ç
¹ÚÀçÈ« ( Park Jae-Hong ) 
ºÎ»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼Ò¾Æ°úÇб³½Ç
ÀÌâÈÆ ( Lee Chang-Hun ) 
ºÎ»ê´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

Abstract

¸ñ Àû: ½Å»ý¾Æ °£³» ´ãÁó Á¤Ã¼ÁõÀ» ÀÏÀ¸Å°´Â ÁúȯµéÀº ÀÓ»óÀûÀ¸·Î °¨º°ÀÌ ¿ëÀÌÇÏÁö ¾ÊÀ¸¸ç, ¿¹ÈÄ¿Í °ü·ÃµÈ ÀÎÀڵ鿡 ´ëÇÑ ¿¬±¸°¡ ºÎÁ·ÇÑ ½ÇÁ¤ÀÌ´Ù.º´¸® Á¶Á÷ °Ë»ç, Ç÷û »ýÈ­ÇÐ °Ë»ç, DISIDA ½ÅƼ±×·¡ÇÇ ¼Ò°ßµé°ú ¿¹ÈÄ¿ÍÀÇ °ü·Ã¼º¿¡ ´ëÇÏ¿© ¾Ë¾Æº¸°íÀÚ º» ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù.

¹æ ¹ý: 1995³â 7¿ùºÎÅÍ 2002³â 7¿ù±îÁöÀÇ ±â°£ Áß ºÎ»ê´ëÇк´¿ø ¼Ò¾Æ°ú¿¡ ½Å»ý¾Æ ´ãÁó Á¤Ã¼ÁõÀ¸·Î ³»¿øÇÑ »ýÈÄ 3°³¿ù À̳» ½Å»ý¾Æ ¹× ¿µ¾Æ Áß °£³» ´ãÁó Á¤Ã¼ÁõÀ¸·Î Áø´ÜµÈ 32¸íÀ» ´ë»óÀ¸·Î, Áø´ÜÈÄ 6°³¿ù ÀÌÀü¿¡ Ç÷û ALTÄ¡°¡ Á¤»óÈ­ µÈ ȯ¾Æµé
À» A±ºÀ¸·Î, Áø´Ü ÈÄ 6°³¿ù ÀÌ»ó Áö¼ÓÀûÀ¸·Î Ç÷ûALTÄ¡°¡ Áõ°¡µÈ ȯ¾ÆµéÀ» B±ºÀ¸·Î ±¸ºÐÇÏ°í, Àǹ«±â·ÏÀ» ¹ÙÅÁÀ¸·Î ÇÑ ÈÄÇâÀû ºÐ¼®À» ÇÏ¿´´Ù. »ýÈ­ÇÐ °Ë»ç·Î´Â Ç÷û ALTÄ¡, ÃÑ ºô¸®·çºó, Á÷Á¢Çü ºô¸®·çºó, alkaline phosphataseÀÇ ÃÖ°íÄ¡ µîÀ» ºñ±³ÇÏ¿´À¸¸ç, °£ »ý°Ë¿¡ ´ëÇÑ ºÐ¼®Àº ´ãÁó°üÀÇ Áõ½Ä, ¹®¸Æ°£ °¡±³Çü¼º, ´ÙÇÙ °£¼¼Æ÷, °£¼¼Æ÷ ºÎÁ¾, ´ã¼¼°ü ¸¶°³ 5°¡Áö Ç׸ñ¿¡ ´ëÇÑ Á¶Á÷ ¼Ò°ßÀ» Á¤µµ¿¡ µû¶óÀÓÀÇ·Î 1Á¡ºÎÅÍ 3Á¡±îÁö Á¡¼öÈ­ÇÏ¿© Á¶»çÇÏ¿´°í,DISIDA ½ÅƼ±×·¡ÇÇ¿¡¼­ ´ã³¶°ú ¼ÒÀåÀÌ º¸ÀÎ ½Ã°£À» µÎ ±º¿¡ ´ëÇÏ¿© ºñ±³ÇÏ¿´´Ù.

°á °ú: ½Å»ý¾Æ °£¿°ÀÌ 29¸í, ½Å»ý¾Æ °£¿°°ú °£³»´ãµµ ºÎÁ·ÁõÀ» µ¿¹ÝÇÑ È¯¾Æ°¡ 3¸íÀÌ¿´´Ù. °£ »ý°Ë °Ë»ç»ó ¿¹ÈÄ°¡ ÁÁÁö ¾ÊÀº ±º¿¡¼­ ´ãÁó°ü Áõ½Ä, ¹®¸Æ°£ °¡±³ Çü¼ºÀÌ ½ÉÇÏ¿´À¸¸ç, ´ÙÇÙ °£¼¼Æ÷, °£¼¼Æ÷ ºÎÁ¾, ´ã¼¼°ü ¸¶°³ÀÇ Á¤µµ´Â ¿¹ÈÄ¿Í °ü·Ã¼ºÀÌ
¾ø¾ú´Ù. »ýÈ­ÇÐ °Ë»ç»ó ALTÀÇ ÃÖ°íÄ¡°¡ ³ôÀº ±º¿¡¼­ ¿¹ÈÄ°¡ ÁÁÁö ¸øÇÏ¿´À¸¸ç, DISIDA ½ÅƼ±×·¡ÇÇÀǴ㳶°ú ¼ÒÀåÀÌ º¸ÀÎ ½Ã°£, ÃÑ ºô¸®·çºó, Á÷Á¢Çü ºô¸®·çºó, alkaline phosphataseÀÇ ÃÖ°íÄ¡´Â ¿¹ÈÄ¿Í °ü·Ã¼ºÀÌ ¾ø¾ú´Ù.

°á ·Ð: ½Å»ý¾Æ °£³» ´ãÁó Á¤Ã¼ÁõÀÌ Àִ ȯÀÚ¿¡¼­ °£ Á¶Á÷ °Ë»ç»ó ´ãÁó°ü Áõ½Ä°ú ¹®¸Æ°£ °¡±³ Çü¼ºÀÌ ½ÉÇϰųª Ç÷û ALTÀÇ ÃÖ°íÄ¡°¡ ³ôÀ»¼ö·Ï ¿¹ÈÄ°¡ ³ª»Ú¹Ç·Î À̵鿡 ´ëÇÑ ÁÖÀÇ ±íÀº °üÂû ¹× °Ë»ç°¡ ÇÊ¿äÇÒ °ÍÀ¸·Î »ý°¢ÇÑ´Ù.

Purpose:The prognosis of neonates with cholestasis is not clear. Some factors, such as high peak bilirubin levels and liver histologic findings have been claimed to affect the prognosis adversely. Our study aims to define which factors influence the prognosis of neonatal intrahepatic cholestasis.

Methods:Retrospective reviews of the medical records were performed in 32 cases with neonatal intrahepatic cholestasis, who were admitted to Department of Pediatrics, Pusan National University Hospital from July 1995 to July 2002. Neonates were classified into 2 groups according to the duration of elevated serum alanine aminotransferase (ALT) levels more or less than 6 months. The data, such as biochemical, histopathologic and radiologic findings, were compared in both groups. Biochemical data included mean peak level of serum ALT, total bilirubin, direct bilirubin, and alkaline phosphatase. Histologic parameters related to lobular architecture, fibrosis, inflammatory infiltration and degenerative features of hepatocytes were arbitrary estimated on a scale of 1 to 3.

Results:There were 19 males and 13 females, whose mean age was 48 days (14~77 days). The peak serum ALT levels were higher in the poor outcome group. Ductular proliferation and portoportal bridging were more severe in the poor outcome group. But the degree of multinucleated hepatocytes, hepatocellular swelling and canalicular plug did not appear to be significantly related to the long-term outcome. The DISIDA scintigraphy by visualization time of gall bladder and intestine was not useful in predicting outcome of neonatal intrahepatic cholestasis.

Conclusion:Neonates who have intrahepatic cholestasis with high serum ALT levels, severe ductular proliferation and portoportal bridging in the liver biopsy specimen should be carefully followed up because they may have a poor prognosis.

Å°¿öµå

Neonatal cholestasis;Intrahepatic cholestasis;Neonate

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS